ScreenerHero

RNXTRenovoRx Inc. Common Stock

NAS · US · Healthcare · Biotechnology · renovorx.com
1.320USD+0.38%Mkt Cap: 59.57M $P/E: —

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is che…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap59.57M $
Enterprise Value50.48M $
Revenue (TTM)1.98M $
Gross Profit796.00K $
Net Income (TTM)-11.17M $
Revenue/Share0.0500 USD
Last Price1.320 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.52
PEG—
EV/EBITDA-3.87
EV/Revenue25.55
P/S30.15
P/B6.63
EPS (TTM)-0.31
EPS (Forward)-0.15
52W Range
0.701077% of range1.505
52W High1.505 USD
52W Low0.7010 USD
Profitability
Gross Margin70.88%
Oper. Margin-368.43%
EBITDA Margin0.00%
Profit Margin-994.48%
ROE-205.98%
ROA-137.96%
Growth
Revenue Growth115.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.97M $
CapEx (TTM)2.00K $
FCF Margin-336.44%
FCF Yield-11.16%
Net Debt-9.09M $
Net Debt/EBITDA0.70
Balance Sheet
Debt/Equity0.04
Current Ratio5.74
Quick Ratio5.29
Book Value/Sh0.1990 USD
Cash/Share0.2100 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.000 USD
Upside (mean)+430.3%
Target Range3.000 USD – 14.00 USD
$3.000+430.3% to mean$14.00
# Analysts4
Ownership
Shares Out.45.13M
Float39.20M
Insiders3.42%
Institutions20.38%
Short Interest
Short Ratio1.4d
Short % Float0.65%
Short % Out.0.63%
Shares Short283.44K
Short (prev mo.)345.82K
Technical
SMA 500.9829 (+34.3%)
SMA 2000.9445 (+39.7%)
Beta0.99
S&P 52W Chg18.16%
Avg Vol (30d)355.04K
Avg Vol (10d)615.76K
Technical Indicators
RSI (14)65.1
MACD0.1013
MACD Signal0.0767
MACD Hist.+0.0246
BB Upper1.408 USD
BB Middle1.087 USD
BB Lower0.7661 USD
BB Width59.08%
ATR (14)0.1048 USD
Vol Ratio (20d)0.51x